[go: up one dir, main page]

USRE40119E1 - Adjunctive therapy - Google Patents

Adjunctive therapy Download PDF

Info

Publication number
USRE40119E1
USRE40119E1 US11/016,680 US1668004A USRE40119E US RE40119 E1 USRE40119 E1 US RE40119E1 US 1668004 A US1668004 A US 1668004A US RE40119 E USRE40119 E US RE40119E
Authority
US
United States
Prior art keywords
antagonist
mime
administered
body weight
effected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US11/016,680
Inventor
Gary D. Hodgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
Original Assignee
Eastern Virginia Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24472058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE40119(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eastern Virginia Medical School filed Critical Eastern Virginia Medical School
Priority to US11/016,680 priority Critical patent/USRE40119E1/en
Application granted granted Critical
Publication of USRE40119E1 publication Critical patent/USRE40119E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Cancer cells may be released into the circulation during surgery or other invasive procedures. It has therefore been suggested that a short, preoperative course of tamoxifen may be beneficial. McGuire, The Optical Timing of Mastectomy: Low Tide or High Tide?, Ann. Intern. Med. 1991, 115:401-403, Editorial. Some clinicians have proposed administering progesterone at the time of surgery to enhance prognosis by interrupting metastatic seeding.
  • the present invention contemplates the acute administration of a GnRH analog (or mime) as a pretreatment to invasive procedures such as surgery for breast, prostate or other cancers in order to decrease the reoccurrence rate.
  • Administration results in the suppression of gonadal steroid dependent growth factors and neovascular processes that contribute to metastasis or recurrence in situ.
  • This invention relates to a therapy adjunctive to an invasive procedure and more particularly, to administering to a person prior to a procedure such as excising a growth or portion thereof, a gonadotropin releasing hormone analog or mime thereof and then conducting the procedure before the effect of the gonadotropin releasing hormone antagonist has dissipated.
  • the conventional invasive procedure for excising a growth is carried out but additionally, a gonadotropin releasing hormone analog or other inhibitor of ovarian steroidal supply impact (“mime”) is administered before that procedure is effected.
  • a gonadotropin releasing hormone analog or other inhibitor of ovarian steroidal supply impact (“mime”) is administered before that procedure is effected.
  • the gonadotropin releasing hormone is a small polypeptide produced in the hypothalamus and is sometimes termed gonadotropic releasing hormone, luteinizing the hormone releasing hormone, GnRH or LHRH. Analogs in the form of antagonists and agonists are known and either can be used.
  • the present invention preferably employs the gonadotropin releasing hormone antagonist.
  • a GnRH antagonist acts by classical competitive receptor occupancy at the level of the GnRH receptor in the anterior pituitary.
  • the more active antagonists can extinguish bioactive gonadotropin secretion within minutes, and in turn deplete gonadal estrogen, progesterone and androgen synthesis and secretion to castrate levels within the first day of treatment without a “flare effect” (stimulation of the receptor system), and in turn, without a delay in therapeutic benefit and without a transient exacerbation by temporary elevations of estrogen and androgen.
  • gonadotropin releasing hormone antagonists can be found, inter alia, in U.S. Pat. Nos. 4,409,208, 4,547,370, 4,565,804, 4,569,927, 4,619,914, and 5,198,533 and in WO 89/01944, the disclosures of which are incorporated herein by reference.
  • Antide a decapeptide represented by the formula D-Ac-D-2-Nal 1 -DpClPhe 2 -D-3-Pal 3 -Ser 4 -NiLys 5 -D-NicLys 6 -Leu 7 -ILys 8 -Pro 9 -D-Ala 10
  • Antide a decapeptide represented by the formula D-Ac-D-2-Nal 1 -DpClPhe 2 -D-3-Pal 3 -Ser 4 -NiLys 5 -D-NicLys 6 -Leu 7 -ILys 8 -Pro 9 -D-Ala 10
  • a substitute for the gonadotropin releasing hormone antagonist or agonist can be employed.
  • the inhibitors of steroid production or action are entities which mimic the activity of the antagonist sufficiently to reversibly inactivate gonadal response or impact of ovarian steroids, including the blockade of gonadotropin stimulated steroidogenesis. Examples include recombinant DNA derived gonadotropins, desialated gonadotropins whether natural or DNA derived, antibodies to gonadotropins, gonadotropic subunit parts, inhibitors of gonadotropin receptor activations (i.e., cell messengers), inhibin/activin and their analogs, and the like.
  • the gonadotropin releasing hormone antagonists or other inhibitors employed in the present invention can be administered in the form of pharmaceutically acceptable non-toxic salts or complexes.
  • the salts include acid addition salts such as for instance hydrochloride, hydrobromide, sulfate, phosphate, nitrate, oxalate, fumarate, gluconate, tannate, maleate, acetate, benzoate, succinate, alginate, malate, ascorbate, tartrate and the like.
  • the complexes can be with metals such as for example zinc, barium, calcium, magnesium, aluminum and the like.
  • any known gonadotropin releasing hormone analog or other inhibitor can be employed.
  • any mode of administration heretofore employed for such agents can also be employed in the practice of the present invention.
  • the route of administration can be any conventional route where the analog is active, for instance orally, intravenously, subcutaneously, intramuscularly, sublingually, percutaneously, rectally, intranasally or intravaginally.
  • the administration form can be a tablet, dragee, capsule, pill, nasal mist, aerosol, solutions suspensions, suppositories and the like.
  • the amount of gonadotropin releasing hormone analog or inhibitor administered is that sufficient to adjust the circulating estrogen to a value below about 20 pg/ml and preferably below about 10 pg/ml.
  • the dose administered is generally about 0.001 to 5 mg/kg of body weight, preferably about 0.05 to 5 mg/kg when administered intramuscularly.
  • a single administration may suffice, although one or more additional administrations can be employed over a time period of about one week or up to 30 days, including daily, weekly or monthly. Since the effects of the administration last for several days, it is preferred that the initial gonadotropin releasing hormone antagonist or mime administration occur at least one day before the surgical procedure.
  • the excising of the growth or a portion thereof e.g. a biopsy
  • endogenous estrogen or progesterone production has been restored spontaneously and causes reversion to preadministration condition.
  • an individual is administered the gonadotropin releasing hormone antagonist specified below intramuscularly or subcutaneously.
  • a biopsy is effected.
  • the antagonist and amount, which is administered after suspension in sesame oil, are:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A growth such as a tumor, hypertrophied tissue or cyst is biopsied or more completely excised subsequent to the administration of an effective amount of a gonadotropin releasing hormone analog or other inhibitor of ovarian steroid production or action.

Description

BACKGROUND OF THE INVENTION
Almost 100 years ago it was recognized that breast cancer exhibited a degree of hormone dependency. Disease regression was achieved through estrogen ablation.
Studies of normal breast tissue indicate that endogenous hormones of the menstrual cycle influence rates of cell division and cell death. Speroff, The Breast, in: Speroff, Ed., Clinical Gynecologic Endocrinology & Infertility, Fourth Edition, Baltimore Williams & Williams: 1989: 629:91-119. Estrogen levels rise sharply and then fall in the absence of progesterone during the follicular phase of the cycle. Following ovulation, levels of these hormones increase and then decline before the onset of menses. The pattern of cyclic hormone concentration has been shown to influence both immune parameters and growth factors.
Laboratory studies have revealed that estrogen influences the growth fraction of human breast adenocarcinomics. When both estrogen and progesterone are present, this growth factor is significantly depressed. Jones, Influence of Steroid Hormones on the Growth Fraction of Human Breast Carcinomas, Am. J. Clin. Pathol. 1987, 88:132-138, Retardation of human breast cancer cells in the presence of progesterone has also been observed.
Cancer cells may be released into the circulation during surgery or other invasive procedures. It has therefore been suggested that a short, preoperative course of tamoxifen may be beneficial. McGuire, The Optical Timing of Mastectomy: Low Tide or High Tide?, Ann. Intern. Med. 1991, 115:401-403, Editorial. Some clinicians have proposed administering progesterone at the time of surgery to enhance prognosis by interrupting metastatic seeding.
The present invention contemplates the acute administration of a GnRH analog (or mime) as a pretreatment to invasive procedures such as surgery for breast, prostate or other cancers in order to decrease the reoccurrence rate. Administration results in the suppression of gonadal steroid dependent growth factors and neovascular processes that contribute to metastasis or recurrence in situ.
It is accordingly the object of the present invention to provide an adjunctive method to be employed in conjunction with the excisement of a neoplasm, cysts or portion thereof. This and other objects of the present invention will become apparent to those of ordinary skill in this from the following detailed description.
SUMMARY OF THE INVENTION
This invention relates to a therapy adjunctive to an invasive procedure and more particularly, to administering to a person prior to a procedure such as excising a growth or portion thereof, a gonadotropin releasing hormone analog or mime thereof and then conducting the procedure before the effect of the gonadotropin releasing hormone antagonist has dissipated.
DESCRIPTION OF THE INVENTION
In accordance with the present invention, the conventional invasive procedure for excising a growth (or portion thereof) is carried out but additionally, a gonadotropin releasing hormone analog or other inhibitor of ovarian steroidal supply impact (“mime”) is administered before that procedure is effected.
The gonadotropin releasing hormone is a small polypeptide produced in the hypothalamus and is sometimes termed gonadotropic releasing hormone, luteinizing the hormone releasing hormone, GnRH or LHRH. Analogs in the form of antagonists and agonists are known and either can be used. The present invention preferably employs the gonadotropin releasing hormone antagonist. A GnRH antagonist acts by classical competitive receptor occupancy at the level of the GnRH receptor in the anterior pituitary. The effect is realized quickly and the more active antagonists can extinguish bioactive gonadotropin secretion within minutes, and in turn deplete gonadal estrogen, progesterone and androgen synthesis and secretion to castrate levels within the first day of treatment without a “flare effect” (stimulation of the receptor system), and in turn, without a delay in therapeutic benefit and without a transient exacerbation by temporary elevations of estrogen and androgen.
Examples of gonadotropin releasing hormone antagonists can be found, inter alia, in U.S. Pat. Nos. 4,409,208, 4,547,370, 4,565,804, 4,569,927, 4,619,914, and 5,198,533 and in WO 89/01944, the disclosures of which are incorporated herein by reference. Examples of such antagonists include Antide (a decapeptide represented by the formula D-Ac-D-2-Nal1-DpClPhe2-D-3-Pal3-Ser4-NiLys5-D-NicLys6-Leu7-ILys8-Pro9-D-Ala10), [Ac-D4ClDPhe1, D4ClDPhe2, DTrp3, DArg6, DAla10] GnRH, [Ac-4ClDPhe2, D3Pal3, Arg5, D2Nal6, DAla10] GnRH, [Ac-D2-Nal1, 4ClDPhe2, DTrp3, DArg6, DAla10]GnRH, [Ac-D2Nal1, 4FDPhe2, DTrp3, DArg6]GnRH, [Ac-D2Nal1, 4-ClDPhe2, DTrp3, DhArg(Et2)6, DAla10]GnRH, and [Ac-Nal1, DME4ClPhe2, DPal3, Ser4, Tyr5, DArg6, Leu7, ILys8, Pro9, DAla10] GnRH.
Further, a substitute for the gonadotropin releasing hormone antagonist or agonist can be employed. The inhibitors of steroid production or action are entities which mimic the activity of the antagonist sufficiently to reversibly inactivate gonadal response or impact of ovarian steroids, including the blockade of gonadotropin stimulated steroidogenesis. Examples include recombinant DNA derived gonadotropins, desialated gonadotropins whether natural or DNA derived, antibodies to gonadotropins, gonadotropic subunit parts, inhibitors of gonadotropin receptor activations (i.e., cell messengers), inhibin/activin and their analogs, and the like.
The gonadotropin releasing hormone antagonists or other inhibitors employed in the present invention can be administered in the form of pharmaceutically acceptable non-toxic salts or complexes. The salts include acid addition salts such as for instance hydrochloride, hydrobromide, sulfate, phosphate, nitrate, oxalate, fumarate, gluconate, tannate, maleate, acetate, benzoate, succinate, alginate, malate, ascorbate, tartrate and the like. The complexes can be with metals such as for example zinc, barium, calcium, magnesium, aluminum and the like.
Any known gonadotropin releasing hormone analog or other inhibitor can be employed. Also any mode of administration heretofore employed for such agents can also be employed in the practice of the present invention. Thus, the route of administration can be any conventional route where the analog is active, for instance orally, intravenously, subcutaneously, intramuscularly, sublingually, percutaneously, rectally, intranasally or intravaginally. Similarly, the administration form can be a tablet, dragee, capsule, pill, nasal mist, aerosol, solutions suspensions, suppositories and the like.
As a rule of thumb, the amount of gonadotropin releasing hormone analog or inhibitor administered is that sufficient to adjust the circulating estrogen to a value below about 20 pg/ml and preferably below about 10 pg/ml. Depending on the particular active agent employed, the dose administered is generally about 0.001 to 5 mg/kg of body weight, preferably about 0.05 to 5 mg/kg when administered intramuscularly. Also depending upon the particular agent employed, a single administration may suffice, although one or more additional administrations can be employed over a time period of about one week or up to 30 days, including daily, weekly or monthly. Since the effects of the administration last for several days, it is preferred that the initial gonadotropin releasing hormone antagonist or mime administration occur at least one day before the surgical procedure. The excising of the growth or a portion thereof (e.g. a biopsy) is carried out in conventional fashion before endogenous estrogen or progesterone production has been restored spontaneously and causes reversion to preadministration condition.
In order to demonstrate the present invention, an individual is administered the gonadotropin releasing hormone antagonist specified below intramuscularly or subcutaneously. One day later, a biopsy is effected. The antagonist and amount, which is administered after suspension in sesame oil, are:
Analog or Mime Dose mg/kg/day
Antide 0.3
Azaline B 0.05
[Ac-D4ClDPhe1, D4ClDPhe2, 0.5
DTrp3, DArg6, DAla10] GnRH
[Ac-4ClDPhe2, D3Pal3, Arg5, 0.5
D2Na]6, DAla10] GnRH
[Ac-D2-Nal1, 4ClDPhe2, 0.5
DTrp3, DArg6, DAla10] GnRH
[Ac-Nal1, DME4ClPhe2, 0.5
DPal3, Ser4, Tyr5, DArg6,
Leu7, ILys8, Pro9, DAla10]
GnRH
Application of the components, compositions and methods of this invention for the medical and/or pharmaceutical use which are described in this text may be accomplished by and clinical, medical or pharmaceutical methods or techniques as are presently or prospectively known to those skilled in the art. The various embodiments which have been described herein were intended to be representative and not limiting, as various changes and modifications can be made in the present invention without departing from the spirit and scope thereof.

Claims (25)

1. A method which comprises administering to an individual a person an effective amount effective to temporarily reduce circulating estrogen of a gonadotropin releasing hormone antagonist or mime thereof selected from the group consisting of antide and azaline B and thereafter conducting an invasive procedure to excise a growth or portion thereof before the effect of the analog antagonist or mime thereof has dissipated.
2. The method of claim 1 wherein the invasive procedure comprises excising a growth or portion thereof.
3. The method of claim 2 1 wherein the antagonist is administered about one day before the excisement.
4. The method of claim 3 in which only a single administration of the antagonist is effected.
5. The method of claim 2 in which only a single administration of the antagonist is effected.
6. The method of claim 5 in which about 0.001 to 5 mg/kg of body weight of antagonist is administered.
7. The method of claim 2 in which about 0.5 to 5 mg/kg of body weight of antagonist is administered.
8. The method of claim 2 1 in which the antagonist is antide.
9. The method of claim 2 1 in which the antagonist is azaline B.
10. The method of claim 1 wherein the antagonist or mime is administered about one day before the invasive procedure.
11. The method of claim 10 in which only a single administration of the antagonist or mime is effected.
12. The method of claim 1 in which only a single administration of the antagonist or mime is effected.
13. The method of claim 1 in which about 0.001 to 5 mg/kg of body weight of antagonist or mime is administrated.
14. The method of claim 1 in which about 0.5 to 5 mg/kg of body weight of antagonist or mime is administered.
15. The method of claim 1 wherein the effective amount is that sufficient to adjust the circulating estrogen to a value below about 20 pg/ml.
16. The method of claim 1 wherein the effective amount is that sufficient to adjust the circulating estrogen to a value below about 10 pg/ml.
17. The method of claim 1 wherein the length of time of administration of the antagonist or mime thereof is about one week.
18. A method which comprises administering to a female person an effective amount of a gonadotropin releasing hormone antagonist or mime thereof, said antagonist or mime acting by competitive receptor occupancy, in an amount effective to adjust the circulating estrogen to a value below about 20 pg/ml, and thereafter conducting an invasive procedure which excises a tissue growth or portion thereof before the effect of the antagonist or mime thereof has dissipated and the circulating estrogen has a value above about 20 pg/ml.
19. The method of claim 18 wherein the effective amount is that sufficient to adjust the circulating estrogen to a value below about 10 pg/ml.
20. The method of claim 18 wherein the length of time of the antagonist or mime thereof administration is about one week.
21. The method of claim 18 wherein the antagonist is administered about one day before the excisement.
22. The method of claim 18 in which only a single administration of the antagonist is effected.
23. The method of claim 18 in which about 0.001 to 5 mg/kg of body weight of antagonist is administrated.
24. The method of claim 23 in which about 0.05 to 5 mg/kg of body weight of antagonist is administrated.
25. The method of claim 18 wherein the tissue growth or portion thereof excised is a tumor, hypertrophied tissue or a cyst.
US11/016,680 1996-03-18 2004-12-20 Adjunctive therapy Expired - Lifetime USRE40119E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/016,680 USRE40119E1 (en) 1996-03-18 2004-12-20 Adjunctive therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/617,048 US5691314A (en) 1996-03-18 1996-03-18 Adjunctive therapy
US11/016,680 USRE40119E1 (en) 1996-03-18 2004-12-20 Adjunctive therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/617,048 Reissue US5691314A (en) 1996-03-18 1996-03-18 Adjunctive therapy

Publications (1)

Publication Number Publication Date
USRE40119E1 true USRE40119E1 (en) 2008-02-26

Family

ID=24472058

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/617,048 Expired - Lifetime US5691314A (en) 1996-03-18 1996-03-18 Adjunctive therapy
US11/016,680 Expired - Lifetime USRE40119E1 (en) 1996-03-18 2004-12-20 Adjunctive therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/617,048 Expired - Lifetime US5691314A (en) 1996-03-18 1996-03-18 Adjunctive therapy

Country Status (7)

Country Link
US (2) US5691314A (en)
EP (1) EP0796622B1 (en)
AT (1) ATE249233T1 (en)
DE (1) DE69724682T2 (en)
DK (1) DK0796622T3 (en)
ES (1) ES2206622T3 (en)
PT (1) PT796622E (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6254601B1 (en) 1998-12-08 2001-07-03 Hysterx, Inc. Methods for occlusion of the uterine arteries
US7223279B2 (en) 2000-04-21 2007-05-29 Vascular Control Systems, Inc. Methods for minimally-invasive, non-permanent occlusion of a uterine artery
US6550482B1 (en) 2000-04-21 2003-04-22 Vascular Control Systems, Inc. Methods for non-permanent occlusion of a uterine artery
US6635065B2 (en) * 2000-11-16 2003-10-21 Vascular Control Systems, Inc. Doppler directed suture ligation device and method
US6638286B1 (en) 2000-11-16 2003-10-28 Vascular Control Systems, Inc. Doppler directed suture ligation device and method
US7354444B2 (en) 2001-03-28 2008-04-08 Vascular Control Systems, Inc. Occlusion device with deployable paddles for detection and occlusion of blood vessels
EP1377223A2 (en) * 2001-03-28 2004-01-07 Vascular Control Systems, Inc. Method and apparatus for the detection and ligation of uterine arteries
US7207996B2 (en) * 2002-04-04 2007-04-24 Vascular Control Systems, Inc. Doppler directed suturing and compression device and method
US7172603B2 (en) * 2002-11-19 2007-02-06 Vascular Control Systems, Inc. Deployable constrictor for uterine artery occlusion
US20040097961A1 (en) * 2002-11-19 2004-05-20 Vascular Control System Tenaculum for use with occlusion devices
US7404821B2 (en) 2003-01-30 2008-07-29 Vascular Control Systems, Inc. Treatment for post partum hemorrhage
US7651511B2 (en) 2003-02-05 2010-01-26 Vascular Control Systems, Inc. Vascular clamp for caesarian section
US7333844B2 (en) 2003-03-28 2008-02-19 Vascular Control Systems, Inc. Uterine tissue monitoring device and method
US7325546B2 (en) * 2003-11-20 2008-02-05 Vascular Control Systems, Inc. Uterine artery occlusion device with cervical receptacle
US7686817B2 (en) 2003-11-25 2010-03-30 Vascular Control Systems, Inc. Occlusion device for asymmetrical uterine artery anatomy
US20060015144A1 (en) * 2004-07-19 2006-01-19 Vascular Control Systems, Inc. Uterine artery occlusion staple
US7875036B2 (en) 2004-10-27 2011-01-25 Vascular Control Systems, Inc. Short term treatment for uterine disorder
US20100197601A1 (en) * 2007-09-11 2010-08-05 Dorian Bevec Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection
US8211856B2 (en) * 2007-09-11 2012-07-03 Mondobiotech Laboratories Ag Use of somatostatin-14 as a therapeutic agent
CN101555274B (en) * 2009-05-15 2013-08-21 海南双成药业股份有限公司 Preparation method of polypeptide solid-phase synthesis bivalirudin crude product

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116818A (en) * 1987-03-10 1992-05-26 Medical College Of Hampton Roads Method and kit for contraception with GnRH-antagonist
US5434138A (en) * 1990-08-04 1995-07-18 Hoechst Aktiengesellschaft Gonadoliberin antagonists
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116818A (en) * 1987-03-10 1992-05-26 Medical College Of Hampton Roads Method and kit for contraception with GnRH-antagonist
US5434138A (en) * 1990-08-04 1995-07-18 Hoechst Aktiengesellschaft Gonadoliberin antagonists
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US5843902A (en) 1995-12-15 1998-12-01 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH antagonists
US6153586A (en) 1995-12-15 2000-11-28 Praecis Pharmaceuticals, Inc. Methods for treating prostate cancer with LHRH-R antagonists
US6180609B1 (en) 1995-12-15 2001-01-30 Praecis Pharmaceuticals, Inc. Methods for treating LHRH associated disorders with LHRH antagonists
US6211153B1 (en) 1995-12-15 2001-04-03 Praecis Pharmaceuticals, Inc. Methods for treating LHRH associated disorders with LHRH antagonists
US6384017B1 (en) 1995-12-15 2002-05-07 Praecis Pharmaceuticals, Inc. Methods for treating sex hormone-dependent conditions with Lhrh antagonists

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Audebert et al., Deferred Versus Immediate Surgery For Uterine Fibroids. Brit. J. of Obstet. and Gyn. 1994. vol. 101, Suppl. 10, pp. 29-32.
Diedrich et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Human Reproduction. 1994, vol. 9, No. 5, pp. 788-791. *
Hellstrom et. al., A 3-Year Follow-Up of Patients. Brit. J. of. Urol. 1996. vol. 78, pp. 432-436.
Ljungqvist et al. Antide and related antagonists of luteinizing hormone release with long action and oral activity. Proc. Natl. Acad. Sci. USA. Nov. 1988, vol. 85, pp. 8236-8240. *
Lumsden et al., Treatment With the Gonadotropin Releasing Hormone-Agonist Goserelin. Brit. J. of Obstet. and Gyn. 1994. vol. 101, pp. 438-442.
Perry et al., Goserelin. Drugs. 1996. vol. 51, No. 2, pp. 319-346.
Rivier et al. Gonadotrophin-Releasing Hormone Antagonists: Novel Members of the Azaline B Family. Journal of Medicinal Chemistry. 1995, vol. 38, No. 14, pp. 2649-2662. *
Soloway et al., Randomized Prospective Study. J. of Urol. 1995. vol. 154, pp. 424-428.
Stovall et al, GnRH Agonist. Obstetrics and Gynecology. 1995, vol. 86, No. 1, pp. 65-71.

Also Published As

Publication number Publication date
DE69724682T2 (en) 2004-07-15
PT796622E (en) 2003-12-31
EP0796622A3 (en) 1999-02-24
DE69724682D1 (en) 2003-10-16
EP0796622A2 (en) 1997-09-24
ES2206622T3 (en) 2004-05-16
EP0796622B1 (en) 2003-09-10
ATE249233T1 (en) 2003-09-15
US5691314A (en) 1997-11-25
DK0796622T3 (en) 2004-01-12

Similar Documents

Publication Publication Date Title
USRE40119E1 (en) Adjunctive therapy
Reissmann et al. The LHRH antagonist cetrorelix: a review
Wallach et al. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs
Gonzalez-Barcena et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix.
EP0785792B1 (en) Treatment of ovarian estrogen dependent conditions
Schally LH-RH analogues: I. Their impact on reproductive medicine
EP0593491B1 (en) Luteinizing hormone releasing hormone antagonist peptides
US5998377A (en) Means for treating prostate cancer
Casper Clinical uses of gonadotropin-releasing hormone analogues
Jacobi et al. Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension
AU8061691A (en) Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
Erickson et al. GnRH analogues in the treatment of endometriosis
AU691952B2 (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
US5824286A (en) Mammography method
US5658884A (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
Jackson et al. LHRH analogues in the treatment of cancer
Moghissi Clinical applications of gonadotropin-releasing hormones in reproductive disorders
EP0811382B1 (en) Mammography method
Akagbosu The use of GnRH agonists and antagonists in infertility
Tolis et al. Application of LHRH and its superactive analogues in reproductive biology
Kardamakis et al. GnRH Analogues in Reproductive Medicine and Gynaecologic Cancer
Sitruk-Ware GnRH analogs in contraception
Helvacioglu Gonadotropin Releasing Hormone Treatment
Moghissi Gonadotropin Releasing Hormones: Physiopathology and Clinical Applications
HK1006172B (en) Luteinizing hormone releasing hormone antagonist peptides

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12